Glycotherapeutics

Immucillin-H molecule.

We are using novel enzyme inhibitor design technology and the elucidation of disease signaling pathways to seek new drug candidates for the treatment of cancer, malaria,  microbial infections and other unmet medical needs.

In collaboration with biology partners in New Zealand and overseas - especially at the Albert Einstein College of Medicine in New York – we will continue to identify, and seek to validate, new biological targets. We will liaise, communicate with and support New Zealand industry and new investment, manufacturing and wealth creation opportunities will be generated for the New Zealand biotech sector.

In the course of this research Industrial Research has:

• designed, synthesised, and licensed Immucillin-H (Fodosine™), a powerful new pharmaceutical for the treatment of T-cell leukemia, B-cell leukemia, and cutaneous T-cell lymphoma.
• designed, synthesised and licensed DADMe-Immucillin-H, a powerful new pharmaceutical for the treatment of psoriasis and T-cell mediated auto-immune diseases.
• designed and synthesised a series of powerful inhibitors of human methylthioadenosine phosphorylase, potentially powerful pharmaceuticals which are currently in pre-clinical development for the treatment of prostate cancer and head and neck tumours. 
• designed and synthesised an entirely new class of potentially powerful antibiotics. 

We continue to investigate the synthesis and biological activity of ‘next’ generation immunospressives, cancer therapeutics and antibiotics.

We are also involved in the rational design of small molecule anti-malarial pharmaceuticals and are investigating the discovery of small molecule structures with anti-diabetic properties that have a potential therapeutic benefit in treating type II diabetes.